Grace Therapeutics Awaits FDA Decision on GTx-104 for Aneurysmal Subarachnoid Hemorrhage with April 2026 PDUFA Date
Key Insights
Grace Therapeutics (search) has received an FDA PDUFA target date of April 23, 2026, for its New Drug Application seeking approval of GTx-104, an intravenous nimodipine formulation for treating aneurysmal subarachnoid hemorrhage (search) (aSAH (search)).
The Phase 3 STRIVE-ON trial demonstrated that GTx-104 reduced clinically significant hypotension (search) by 19% compared to oral nimodipine (28% vs 35%) and showed 29% more patients achieving favorable functional outcomes at 90 days.
The company reported $18.7 million in cash as of December 31, 2025, which management believes sufficient to sustain operations through at least 12 months while continuing pre-commercial planning activities.
Grace Therapeutics (search) has received a Prescription Drug User Fee Act (PDUFA) target date of April 23, 2026, from the FDA for its New Drug Application (NDA) seeking approval of GTx-104 for treating patients with aneurysmal subarachnoid hemorrhage (search) (aSAH (search)). The company announced its third quarter 2026 financial results while continuing pre-commercial planning in anticipation of potential FDA approval.
STRIVE-ON Trial Results Support Regulatory Submission
The NDA is supported by positive results from the pivotal Phase 3 STRIVE-ON safety trial, which compared GTx-104 with oral nimodipine in 102 patients hospitalized with aSAH (search). The trial met its primary endpoint, demonstrating that patients receiving GTx-104 had a 19% reduction in at least one incidence of clinically significant hypotension (search) compared to oral nimodipine (28% versus 35%).
"Our NDA is supported by a robust data package, including positive results from our STRIVE-ON trial, which provided evidence of improved clinical outcomes in aSAH (search) patients treated with GTx-104 as well as potential medical and pharmacoeconomic benefits," said Prashant Kohli, CEO of Grace Therapeutics (search).
The trial also showed additional benefits favoring GTx-104: 54% of patients on GTx-104 had relative dose intensity of 95% or higher compared to only 8% on oral nimodipine, and 29% more patients on GTx-104 than on oral nimodipine had favorable functional outcomes at 90 days. Patients receiving GTx-104 experienced fewer intensive care unit readmissions, ICU days, and ventilator days compared to those receiving oral nimodipine.
Safety Profile and Clinical Advantages
Adverse events were comparable between the two treatment arms, and no new safety issues were identified with GTx-104. All deaths in both arms were attributed to the severity of the patient's underlying disease rather than the treatments. The trial recorded eight deaths on the GTx-104 arm compared to four deaths on the oral nimodipine arm, with one patient's survival status unknown on the oral nimodipine arm.
GTx-104's unique nanoparticle technology facilitates aqueous formulation of insoluble nimodipine for standard peripheral IV infusion, potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. The intravenous delivery also has the potential to reduce food effects, drug-to-drug interactions, and dosing errors while better managing hypotension (search) in aSAH (search) patients.
Addressing Significant Unmet Medical Need
Aneurysmal subarachnoid hemorrhage (search) is bleeding over the surface of the brain in the subarachnoid space between the brain and skull, primarily caused by the rupture of a brain aneurysm. This relatively uncommon type of stroke (search) accounts for about 5% of all strokes and affects an estimated 42,500 U.S. hospital-treated patients annually.
"The standard of care for aSAH (search) has not seen meaningful innovation in nearly 40 years, and we believe that if GTx-104 is approved, our STRIVE-ON trial results point to a very promising role for GTx-104 in the treatment of these patients," Kohli noted.
Financial Position and Commercial Preparation
Grace Therapeutics (search) reported a net loss of approximately $2.3 million, or $0.14 per share, for the three months ended December 31, 2025, representing a decrease from the $4.2 million net loss in the same period of 2024. The improvement was primarily due to reduced research and development expenses following completion of the STRIVE-ON trial.
As of December 31, 2025, the company held $18.7 million in cash and cash equivalents. Management believes this funding will be sufficient to sustain planned operations through at least 12 months while supporting the regulatory review process, pre-commercial planning, and potential product launch if approved.
The company has been actively preparing for potential commercialization, including providing grant support for the development of a Continuing Medical Education program for healthcare professionals treating aSAH (search) patients. The STRIVE-ON trial data was presented as a late-breaking presentation at the Society of Vascular and Interventional Neurology (search) annual meeting in November 2025.
GTx-104 has received Orphan Drug Designation from the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval. The company's intellectual property portfolio includes over 40 granted and pending patents supporting its drug candidates.